Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice
- PMID: 28374308
- PMCID: PMC5378729
- DOI: 10.1007/s11894-017-0554-0
Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice
Abstract
Purpose of review: The purpose of the review was to provide an update of the Rome IV criteria for colorectal disorders with implications for clinical practice.
Recent findings: The Rome diagnostic criteria are expert consensus criteria for diagnosing functional gastrointestinal disorders (FGIDs). The current version, Rome IV, was released in May of 2016 after Rome III had been in effect for a decade. It is the collective product of committees that included more than 100 leading functional GI experts. For functional bowel and anorectal disorders, the majority of changes relative to Rome III are relatively minor and will have little impact on clinical practice. However, notable changes with potential impact on clinical practice and research include the changes in the diagnostic criteria for IBS, the modified approach for subtyping of IBS, the view on functional bowel disorders as a spectrum of disorders, and the new definition of fecal incontinence. New features in the Rome IV diagnostic criteria for functional bowel and anorectal disorders will likely have modest influence on clinical practice, with a few exceptions.
Keywords: Fecal incontinence; Functional GI disorders; Functional anorectal disorders; Functional bowel disorders; Irritable bowel syndrome; Rome IV diagnostic criteria.
Conflict of interest statement
Conflict of Interest
Magnus Simren reports grants and personal fees from Danone Research, personal fees from Allergan, grants from Ferring Pharmaceuticals, personal fees from Takeda, personal fees from Menarini, personal fees from Tillotts, personal fees from Shire, personal fees from Almirall, personal fees from Glycom, personal fees from Albireo, personal fees from AstraZeneca, outside the submitted work.
Olafur Palsson reports grants from Takeda Pharmaceuticals, grants from Salix Pharmaceuticals, personal fees from Glycom, personal fees and other from MetaMe Health LLC, grants from Ironwood Pharmaceuticals, grants and personal fees from Rome Foundation, outside the submitted work.
Williams Whitehead reports grants and personal fees from Takeda Pharmaceuticals, grants and personal fees from Ferring Pharmaceuticals, personal fees from Ono Pharmaceuticals, personal fees from Biomerica USA, grants and personal fees from Ironwood Pharmaceuticals, outside the submitted work.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials